Use of active pharmaceutical compounds for the treatment of central nervous system conditions

摘要

The present invention relates to the pharmaceutical use of selective GABA Aα5 negative allosteric modulators for the treatment, prevention and/or delay of progression of central nervous system (CNS) conditions related to excessive GABAergic inhibition in the brain.